Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
185 Leser
Artikel bewerten:
(0)

Crown Bioscience Enables Secure Data Real Time Access with the Release of Client Facing Portal

SANTA CLARA, Calif., March 9, 2017 /PRNewswire/ -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expedited their access to study data with the release of a new, secure online data portal.

Crown Bioscience

The proprietary, client data portal was created in alignment with an ongoing strategic initiative to utilize digital platforms to drive increased customer value. Developed internally by CrownBio's bioinformatics group, the platform provides real-time research results allowing clients continuous access to their data.

This innovative tool enables client to perform data manipulation online, or download the study results in multiple formats. Clients may also import their data into their systems and perform further analysis within their chosen application.

"We live in an era where technology allows people to access data when and where they choose. At CrownBio, we want to bring this high-speed standard to our clients in a secure and user-friendly manner," stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. Heilmann continued, "We understand how important the data is to our clients; and therefore, we have developed a portal that will permit our clients to have secure access to their project updates and datasets at any time."

This first release of the data portal contains essential filtering capabilities. Future releases will add to the core feature set and be driven entirely by a customer advisory and governance panel.

"This governance group will shape the development of the portal, ensuring that our digital tools reflect the needs of our customers and solve real-world challenges," commented Gavin Cooper, Executive Director of Marketing.

For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com

About Crown Bioscience Inc.

Crown Bioscienceis a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Logo - http://mma.prnewswire.com/media/351602/crown_bio_Logo.jpg

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.